Today’s Research Reports on Stocks to Watch: Mylan and Pfizer

NEW YORK, NY / ACCESSWIRE / April 4, 2017 / Mylan’s recent string of bad news continued Monday after it was revealed that the previously announced recall of EpiPens would also include U.S. EpiPen and EpiPen Jr. There were two cases from outside of the U.S. where the EpiPen had failed to activate “due to a potential defect in a supplier component,” Mylan said. The defective EpiPens were manufactured by a Pfizer subsidiary, Meridian Medical Technologies.

RDI Initiates
Coverage on:

Mylan https://ub.rdinvesting.com/news/?ticker=MYL

Pfizer https://ub.rdinvesting.com/news/?ticker=PFE

Mylan’s shares gained 0.05% to close at $39.01 on Monday. The stock traded between $38.57 and $39.16 on volume of 7.58 million shares traded. The EpiPens recall has now been expanded to 13 lots, which were sold in the U.S. between December 2015 and July 2016. However, the exact number to be recalled has not yet been revealed. Mylan acquired EpiPen in 2007 and has since increased the price by more than 500% to $609 for a two-pack of the product. On Monday, a lawsuit was filed in federal court accusing the company of overcharging EpiPen patients. Shares of Mylan have gained approximately 2.25 percent year-to-date.

Access RDI’s Mylan’s Research Report at: https://ub.rdinvesting.com/news/?ticker=MYL

Pfizer’s shares gained 0.09% to close at $34.24 on Monday. The stock traded between $34.10 and $34.35 on volume of 18.09 million shares traded. On March 31st, the company announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application (sNDA) for IBRANCE (palbociclib). “The FDA action converts the accelerated approval of IBRANCE to regular approval and broadens the range of anti-hormonal therapy that may be administered with IBRANCE,” Pfizer reported in the press release. Shares of Pfizer have gained approximately 5.42 percent year-to-date.

Access RDI’s Pfizer Research Report at: https://ub.rdinvesting.com/news/?ticker=PFE

Our Actionable Research on Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458935